Literature DB >> 11857360

Incidence and mortality from stomach cancer in Japan, Slovenia and the USA.

René Lambert1, Agathe Guilloux, Akira Oshima, Vera Pompe-Kirn, Freddie Bray, Max Parkin, Wakiko Ajiki, Hideaki Tsukuma.   

Abstract

The mortality and incidence from stomach cancer were compared in Japan (a country with a high incidence where there was full application of mass screening during this period) and 2 countries with no screening policy: the USA (with a very low incidence) and Slovenia (with an intermediate rate). The registered cases of stomach cancer were from the Osaka Cancer Registry, the Slovenian National Cancer Registry and the Surveillance, Epidemiology, and End Results (SEER) registries in the USA. In the period 1975-95, the age-adjusted incidence rate (/100,000) of stomach cancer declined in the 3 countries, as follows: Japan, from 76.0 to 53.0 in men and 38.4 to 21.3 in women; Slovenia, from 40.2 to 24.1 in men and 16.6 to 10.8 in women; and the USA, from 9.5 to 6.9 in men and 4.3 to 2.9 in women. During the same period, the age-adjusted mortality rate declined, as follows: Japan, from 60.2 to 34.2 in men and 30.5 to 14.1 in women; Slovenia, from 37.7 to 21.2 in men and 13.8 to 9.0 in women; the USA, from 5.6 to 4.7 in men and 2.5 to 2.3 in women. In the period studied, specific trends on incidence and mortality with a cohort effect occurred only in Japan: analysis by the age period-cohort model confirmed that the decline has occurred since the generations born in 1910. The trend therefore corresponds to unplanned prevention through changes in environmental factors occurring since the early 20th century. The study of stage-specific incidence rates confirmed the declining trend for regional cancer, whereas there was an increase in the incidence of localized cancer, associated with a period effect in 1975-95. This is attributed to the policy of early detection of stomach cancer, with the inclusion of intramucosal lesions of favorable prognosis and explains why mortality decreased faster than incidence during the period. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11857360     DOI: 10.1002/ijc.10150

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Efficacy of premedication with activated Dimethicone or N-acetylcysteine in improving visibility during upper endoscopy.

Authors:  Seyed Mohammad Kazem Hosseini Asl; Gholam Reza Sivandzadeh
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Management and outcome of gastric carcinoma in Zaria, Nigeria.

Authors:  A Ahmed; A Y Ukwenya; J G Makama; I Mohammad
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

3.  Comparing mass screening techniques for gastric cancer in Japan.

Authors:  Atsushi Tashiro; Masatoshi Sano; Koichi Kinameri; Kazutaka Fujita; Yutaka Takeuchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

4.  Endoscopy in screening for digestive cancer.

Authors:  René Lambert
Journal:  World J Gastrointest Endosc       Date:  2012-12-16

Review 5.  Epidemiology of gastric cancer in Japan.

Authors:  M Inoue; S Tsugane
Journal:  Postgrad Med J       Date:  2005-07       Impact factor: 2.401

6.  Features of Gastric Neoplasm Detected during the Screening Examination.

Authors:  Min Jung Park; Dong Hee Kim; Seon Hee Lim; Jeong Yoon Yim; Young Sun Kim; Kyung Ran Cho; Chung Hyeon Kim; Hyun Chae Jung; In Sung Song; Sun Sin Kim; Dae Hyun Yoon; Chan Soo Shin; Sang-Heon Cho; Byung-Hee Oh; Dong Ho Lee
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

7.  Clinical profile of gastric cancer in Khuzestan, southwest of Iran.

Authors:  Hajiani Eskandar; Sarmast Shoshtari Mohammad Hossein; Masjedizadeh Rahim; Hashemi Jalal; Azmi Mehrdad; Tahereh Rajabi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

8.  The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Tumour Biol       Date:  2014-05-07

9.  Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.

Authors:  Thomas Thomaidis; Arndt Weinmann; Martin Sprinzl; Stephan Kanzler; Jochen Raedle; Matthias Ebert; Carl Cristoph Schimanski; Peter Robert Galle; Thomas Hoehler; Markus Moehler
Journal:  Int J Clin Oncol       Date:  2013-03-27       Impact factor: 3.402

10.  Firm measures are required to effect any significant decrease in the Japanese age-adjusted mortality rate from malignant neoplasms for the 21st century.

Authors:  Shigeyuki Nakaji; Qiang Liu; Tatsuya Yamamoto; Yukika Kakuta; Juichi Sakamoto; Kazuo Sugawara; John C Bailar
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.